Merck gave a number of scientific discussions, including Phase 3 data on ertugliflozin and information on Januvia, this month at the 77th Scientific Sessions of the American Diabetes Association.
Merck has partnered with Pfizer to create ertugliflozin. The data Merck was scheduled to discuss on ertugliflozin included how effective and safe the medication is with sitagliptin, also known as Januvia, compared to using the drugs separately in treating Type 2 diabetes that metformin does not effectively manage, according to a press release. The time period for testing these medications was a year.
Merck also discussed how ertugliflozin impacted the ability of a person with diabetes to control blood sugar, how the medicine affected weight, how it affected blood pressure and how it affected bone strength in people who could not effectively manage diabetes with metformin alone, the release said.
Merck also planned to discuss ertugliflozin's effectiveness in Type 2 diabetes in people who could not effectively manage the disease by just diet and exercise, as well as the long-term safety and efficacy of ertugliflozin as the lone medication for people who couldn't manage the disease with diet and exercise alone. The long-run results were based on a yearlong trial.